To investigate the effects of different doses of aspirin on serum C-reactive protein level in patients with coronary heart disease.

A total of 120 patients with coronary heart disease admitted to Chengyang People's Hospital of Qingdao from January 2017 to March 2018 were selected as observation group. All patients were randomly divided into group A, B and C, 40 cases in each group. Forty healthy persons in the same period were selected as control group. All patients in group A, B and C received oral aspirin. The dosage of aspirin was 50 mg/d in group A, 150 mg/d in group B, and 300 mg/d in group C. The duration of treatment was 1 month. Serum C-reactive protein levels in different groups before and after treatment were compared.

The level of serum C-reactive protein in the observation group was (4.75 ±0.18) mg/L, while that in the control group was (2.82±1.09) mg/L. The level of serum C-reactive protein in the observation group was higher than that in the control group (P<0.05). Before treatment, there was no significant difference in serum C-reactive protein levels among group A, B and C (P>0.05). There was no significant difference in serum C-reactive protein level between group A and B after treatment (P>0.05). The level of C-reactive protein in group C after treatment was lower than that before treatment (P<0.05), and lower than that after treatment in group A and B (P<0.05).

The level of serum C-reactive protein in patients with coronary heart disease is higher than that in healthy people. High dose of aspirin (300 mg/d) can effectively reduce the level of C-reactive protein.